Aurobindo Pharma Limited has successfully completed its acquisition of the Contract Research Services business of A1 Biochem Group. The transaction was executed through Aurobindo's wholly owned subsidiary, Apitoria Pharma Private Limited, following the fulfillment of all conditions outlined in the definitive agreements.

Following the completed transaction, Apitoria Pharma Private Limited now owns 80% of A1 Biochem Labs (India) Private Limited, while former A1 Biochem Group promoter Dr. Rajendra Gadikota holds a 20% minority interest.

To drive its international growth, A1 Biochem Labs (India) Private Limited utilizes a multi-tiered US structure. Its wholly owned subsidiary, A1 Biochem USA Inc., holds a 100% membership interest in A1 Biochem Labs LLC, making the latter a step-down subsidiary operating directly in the US market.

Through this acquisition, Apitoria integrates an established Contract Research Organization (CRO) into its operations. The platform brings a proven track record of delivering over 800 projects across India and the U.S., supported by a strong commercial base of more than 50 active clients.

By blending A1 Biochem Group’s advanced research with Apitoria’s manufacturing scale, the company is launching a fully integrated CRDMO platform. This synergy broadens Apitoria's service offerings and extends customer relationships throughout the product lifecycle, providing global pharma partners with complete, end-to-end solutions.